Hints and tips:
Showing results for Merck Sharp & Dohme Corp., f/k/a Merck & Co., Inc.
...A spokesperson for Merck Sharp & Dohme – the name under which the US group operates in Europe – said it is cooperating fully with the CMA’s investigation, and said: MSD is confident that the proceedings...
...Mergers led the US company to become known as Merck Sharp & Dohme, which prompted a 1950s agreement for it to keep exclusive rights to the Merck name in North America while calling itself MSD everywhere...
...Mergers led the US company to become known as Merck Sharp & Dohme, and this spurred a 1950s agreement for it to keep exclusive rights to the family name in North America while calling itself MSD everywhere...
...Merck’s outperformance stands in sharp contrast to rival Pfizer, which cut its full-year guidance after it warned that a strengthening dollar was hurting its performance....
...Q4 SKr3.45 (SKr1.13) ExxonMobil Q4 $2.01 ($1.97) Mattel Q4 $1.15 ($1.07) Merck & Co Q4 $0.81 ($0.97) Mitsubishi UFJ Financial Group Q3 Y13.44 (Y8.50) Trading and sales update OMV Shareholder meeting...
...These sharp losses weighed on the S&P healthcare index, which fell0.5 per cent to 371.88....
...Rising fears of contagion to Spain and Portugal in the wake of Greece’s fiscal and debt problems sparked a sharp sell-off in US stocks on Tuesday, with sentiment further damped by uncertainty over the full...
...A rally among financial stocks helped Wall Street to shrug off a sharp drop in the oil price and push higher on Wednesday....
...Analysis of the bidders’ operational performance one year before a deal and three years after the combined group was created showed a sharp deterioration....
...Bristol-Myers Squibb gave up 2.9 per cent to $22.12, while Merck lost 1.7 per cent to $32.32....
...AstraZeneca has agreed development projects with Bristol-Myers Squibb on a diabetes drug and with Merck for a cancer treatment....
...Withdrawing the rights outside the US and Asia from Schering-Plough of Remicade would mark a sharp blow to Merck’s acquisition by reducing annual sales by more than $2bn and sacrificing sales forecast after...
...He said investors seemed concerned by the reported collapse of a deal between Rio Tinto and Chinalco. Sanofi-Aventis rose 3.4 per cent to €46.42 and Merck gained 2.6 per cent to €68.60....
...Macy’s and JC Penney– both of which disclosed sharp drops in like-for-like sales – advanced 6 per cent to $7.83 and 7.5 per cent to $19.88, respectively....
...Fuelled by safety concerns since the withdrawal in 2004 of Vioxx, Merck’s painkiller, and scares last year around Avandia, GlaxoSmithKline’s diabetes treatment, companies accuse the US Food & Drug Administration...
...Radical government measures to help mortgage companies Fannie Mae and Freddie Mac and a sharp drop in oil prices also helped....
...Wall Street was rattled in morning trade by a sharp jump in China’s gross domestic product, which raised fears that the country might lift interest rates to cool the economy....
...On Wednesday, fears that a sharp slide in Chinese stocks overnight would spark a similar reaction on Wall Street faded early. Stocks opened lower but losses were quickly contained....
...The New York Stock Exchange said it had asked M&F Worldwide if there were any corporate developments to explain the 10.9 per cent fall in its share price to $37.15....
...Procter & Gamble was one of the best performing stocks with a rise of 3.6 per cent to $63.49. There was little to explain the sharp rise except for investors seeking a safe haven....
...US stocks rallied on Tuesday, as investors digested an array of earnings reports, a sharp jump in oil prices and waited for the Federal Reserve to conclude its policy meeting later on Wednesday....
...drugs with Merck....
...Major pharmaceutical groups have also surged, with Merck rising 18 per cent, Pfizer 15 per cent and Forest Labs 34 per cent....
...The gains would have been more impressive but for sharp afternoon selling of pharmaceutical group Merck , which lost 5.7 per cent to $38.83 after a state judge allowed a retrial for a man who blamed his...
...Shares in HCA, which reported a sharp fall in second-quarter earnings, gained 3.4 per cent to $49.48. Other stocks in the healthcare sector were also higher....
International Edition